Key result
Rivaroxaban triggers reversible leukocytoclastic vasculitis in a young adult.
Why the study?
Leukocytoclastic vasculitis can be triggered by drug reactions, but cases caused by the novel anticoagulant rivaroxaban are not well documented.
Case Report (n=1)
Rivaroxaban may be a potential trigger for cutaneous leukocytoclastic vasculitis.
Rivaroxaban may trigger LCV in patients with purpura; this Level 5 report leaves open causality and class effect.
Cutaneous leukocytoclastic vasculitis (LCV) is type of small vessel vasculitis that commonly presents as palpable purpura involving the lower extremities and buttocks. Approximately half of cases are idiopathic, but the disease may be triggered by infection, drug reaction, inflammatory disease, or other causes. We report a case of leukocytoclastic vasculitis secondary to the novel anticoagulant rivaroxaban (Xarelto®).
No takes yet. Share an insight, caveat, or question.
Dean et al. (2017) conducted a case report in Leukocytoclastic vasculitis (n=1). Rivaroxaban was evaluated on Development of leukocytoclastic vasculitis. Rivaroxaban administration triggered leukocytoclastic vasculitis in a 38-year-old woman, which resolved following discontinuation of the medication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: